Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Monte Rosa Therapeutics (GLUE) Shares Outstanding (2023 - 2025)

Monte Rosa Therapeutics (GLUE) has 3 years of Shares Outstanding data on record, last reported at $1.8 million in Q3 2025.

  • For Q3 2025, Shares Outstanding rose 18.35% year-over-year to $1.8 million; the TTM value through Sep 2025 reached $1.8 million, up 18.35%, while the annual FY2024 figure was $3.2 million, 2.93% down from the prior year.
  • Shares Outstanding reached $1.8 million in Q3 2025 per GLUE's latest filing, down from $1.9 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $4.8 million in Q1 2023 and bottomed at $1.1 million in Q2 2024.
  • Average Shares Outstanding over 3 years is $2.5 million, with a median of $1.9 million recorded in 2025.
  • Peak YoY movement for Shares Outstanding: crashed 75.64% in 2024, then skyrocketed 68.71% in 2025.
  • A 3-year view of Shares Outstanding shows it stood at $3.3 million in 2023, then fell by 2.93% to $3.2 million in 2024, then crashed by 44.82% to $1.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding were $1.8 million in Q3 2025, $1.8 million in Q2 2025, and $2.0 million in Q1 2025.